Zealand Pharma A/S (0NZU.L)
| Previous close | 118.72 |
| Open | 123.20 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 123.20 - 124.50 |
| 52-week range | 123.20 - 124.50 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Zealand Pharma Announces Financial Results for the First Half of 2022
Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half of 2022 Copenhagen, DK and Boston, MA, U.S. August 11, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced financial results for the first half of 2022 and provided a corporate update. Key strategic objectives achieved Adam Steensberg, President an
- Globe Newswire
Updated notice to holders of ADSs regarding termination of Deposit Agreement
NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”)EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”)REPRESENTING DEPOSITED ORDINARY SHARES OF:ZEALAND PHARMA A/S ONE ADS REPRESENTS ONE COMMON SHARECUSIP: 98920Y304 AND UNDERLYING ISIN: DK0060257814 Company announcement – No. 33 / 2022 Copenhagen, DK and Boston, MA, August 8, 2022 – Zealand Pharma A/S (“Zealand” or the “Company”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-headquartered biotechnology company focused on the discovery and
- Globe Newswire
Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market
Company announcement – No. 32 / 2022 Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market Zealand will consolidate trading to Nasdaq Copenhagen, the company’s primary and most liquid stock exchangeDecision is part of Zealand’s refocused strategy to prioritize R&D and streamline corporate operations Copenhagen, DK and Boston, MA, U.S. August 8, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnol
